PAISLEY CHRISTOPHER B sold $18K of AMBA

PAISLEY CHRISTOPHER B sold 250 shares of AMBARELLA INC (AMBA) at $70.76 on 2026-09-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · PAISLEY CHRISTOPHER B
Published Sep 28, 2026, 9:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 2:49 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AMBA
Bearish
medium confidence
Mentioned
$AMBA
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMBABearishLow
01

Why it matters

The director's sale, though small, provides fresh data on insider sentiment and may influence short‑term price dynamics.

02

Market read

A routine insider sale with modest size; likely limited price impact but worth noting for short‑term traders.

03

What to watch

The director's overall holdings remain sizable (43,930 shares), indicating continued confidence in the company.

Relevance 2/10Novelty 2/10Timing: post‑market filing

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$AMBABearishMedium confidence
Context

Director Christopher Paisley sold 250 shares for $17,690 via a 10b5-1 plan on Sep 25, 2026.

Expected impact

likely slight pressure as the market prices in the insider sell

Evidence & confidence

The sale is modest in size but reflects a director reducing his stake, which can be interpreted as a bearish signal.

Market effects

Minimal impact on the biotech sector; the transaction size is too small to move sector sentiment.

No notable regional effect; the filing is a routine insider transaction.

Limited global relevance; only relevant to investors tracking AMBA.

Counterpoint

The sale may be routine portfolio rebalancing rather than a negative signal, so the stock could remain stable.

Key entities

  • AmbaRELLA Inc.

    Biotech company listed on Nasdaq under ticker AMBA.

  • Christopher Paisley

    Director of AmbaRELLA who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AMBAMed

Ambarella (AMBA) Shares Rise 2.4% Amid Nvidia Acquisition Specul

Ambarella (AMBA) shares rose 2.4% on reports Nvidia (NVDA) may join acquisition talks, alongside NXP (NXPI) and Qualcomm (QCOM). The company's P/S ratio is 6.7x, below historical and industry medians, reflecting market skepticism. Insider activity shows $17.1M in sales over the past year. Ambarella specializes in low-power semiconductor solutions for video and AI applications.

$AMBAHighAI 8/10

Ambarella speculated to have a rival suitor - Betaville

Ambarella (AMBA) may have a second potential buyer, following reports of NXP Semiconductors (NXPI) exploring an acquisition. Traders suggest a bid of 75% cash and 25% shares, valued between $95 and $105 per share, citing a Betaville alert. The identity of the new suitor is unknown.

$AMBAHighAI 9/10

ZEDEDA Deal Targets $30B Edge AI Market

Ambarella and ZEDEDA announced a partnership on September 15, 2026, integrating ZEDEDA's EVE-OS with Ambarella's N1 edge AI chips. The deal targets the $30B edge AI market, with developer kits expected in Q4 2026. Ambarella reported Q2 2026 revenue of $108.1M, up 13.2% YoY, while ZEDEDA has raised over $129M in funding.